U-Protein Express BV, an ImmunoPrecise Antibodies company, has successfully secured $3.0 million in new investment capital from investors. This funding round marks a significant milestone for the company, which specializes in providing recombinant antibodies and proteins as a dedicated service provider to the life sciences industry. The capital infusion is intended to fuel the company's strategic growth and enhance its operational capabilities.
As a Contract Research Organization (CRO), U-Protein Express BV brings many years of experience to recombinant protein production. The company is recognized for its proprietary r-PEx transient expression platform, which utilizes Human Embryonic Kidney cells (HEK293E) to produce fully post-translational modified mammalian recombinant proteins or recombinant antibodies. This advanced platform is capable of yielding between 1 mg and 1 gram of recombinant protein within an efficient 4-6 week timeframe, addressing critical needs in biopharmaceutical research and development.
The $3.0 million in secured funding will be instrumental in accelerating U-Protein Express BV's expansion plans. The company intends to deploy the capital to further develop its r-PEx expression platform, scale its production capacities, and broaden its portfolio of service offerings. This investment will enable U-Protein Express BV to meet the growing demand for high-quality recombinant proteins and antibodies, supporting its clients' research and therapeutic development efforts more effectively.
This funding round underscores investor confidence in U-Protein Express BV's innovative technology and its established position within the biopharmaceutical services market. The company is poised for continued growth, aiming to solidify its role as a leading provider of essential research tools and services, thereby contributing to advancements in drug discovery and development globally.
